GlassScriptPhysician profile
Rachel Wint
NPI 1649751843
$10,384.92
in general payments reported to CMS, 2019-2025
68 companies · $26.17 in 2025
The $26.17 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,350 · 2022: $2,964 · 2023: $2,839 · 2024: $2,206 · 2025: $26.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,071.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $1,140.75 | 2021-2022 | |
| Janssen Biotech, INC. | $872.66 | 2021-2024 | Erleada, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $863.91 | 2021-2024 | |
| Astellas Pharma US INC | $692.36 | 2021-2024 | Xtandi, Padcev, Myrbetriq |
| Sumitomo Pharma America, INC. | $553.24 | 2023-2024 | Orgovyx, Gemtesa |
| Novartis Pharmaceuticals Corporation | $546.35 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $541.03 | 2021-2024 | Erleada, Balversa |
| Medtronic, INC. | $454.86 | 2022-2024 | Interstim |
| Teleflex LLC | $303.40 | 2021-2024 | Urolift |
| Genzyme Corporation | $278.46 | 2022-2023 | |
| Dendreon Pharmaceuticals LLC | $242.69 | 2021-2024 | Provenge |
| Incyte Corporation | $220.54 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $210.46 | 2021-2024 | |
| Abbvie INC. | $199.91 | 2021-2024 | |
| Tolmar Pharmaceuticals, INC. | $190.14 | 2021-2022 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Wint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.